BSX:NYE-Boston Scientific Corporation (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 43.73

Change

-0.59 (-1.33)%

Market Cap

USD 63.11B

Volume

6.99M

Avg Analyst Target

USD 50.60 (+15.71%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-27 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABT Abbott Laboratories

-0.42 (-0.33%)

USD227.15B 31.79 21.65
MDT Medtronic plc

-1.55 (-1.25%)

USD166.95B 43.39 23.39
SYK Stryker Corporation

-4.68 (-1.71%)

USD103.02B 50.06 29.77
EW Edwards Lifesciences Corporati..

-0.92 (-0.79%)

USD72.92B 50.78 55.74
PHG Koninklijke Philips N.V

-0.59 (-1.24%)

USD43.74B 19.46 39.66
ZBH Zimmer Biomet Holdings Inc

-3.52 (-2.35%)

USD31.54B 58.31 18.04
STE STERIS plc

-3.25 (-1.38%)

USD23.48B 71.80 39.19
BIO Bio-Rad Laboratories Inc

-8.53 (-1.10%)

USD22.81B 5.77 3.98
BIO-B Bio-Rad Laboratories Inc

N/A

USD22.73B 5.44 3.98
SNN Smith & Nephew plc

-0.54 (-1.50%)

USD15.71B 26.84 15.12

ETFs Containing BSX

Symbol Name Weight Mer Price(Change) Market Cap
IHI iShares U.S. Medical Devi.. 0.00 % 0.42 %

-0.45 (-0.69%)

USD8.16B
LNGR Global X Aging Population.. 0.00 % 0.50 %

N/A

USD0.04B
GDNA Goldman Sachs Human Evolu.. 0.00 % 0.50 %

N/A

USD0.06B
HTEC Robo Global Healthcare Te.. 0.00 % 0.68 %

-0.58 (-1.24%)

USD0.24B
BSCU Invesco BulletShares 2030.. 0.00 % 0.10 %

+0.10 (+0.51%)

N/A
AGNG Global X Aging Population.. 0.00 % 0.50 %

-0.39 (-1.29%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.64% 68% D+ 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.64% 68% D+ 66% D
Trailing 12 Months  
Capital Gain 28.35% 64% D 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.35% 64% D 44% F
Trailing 5 Years  
Capital Gain 97.96% 44% F 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 97.96% 44% F 74% C
Average Annual (5 Year Horizon)  
Capital Gain 13.59% 36% F 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.59% 28% F 65% D
Risk Return Profile  
Volatility (Standard Deviation) 17.50% 72% C- 64% D
Risk Adjusted Return 77.69% 48% F 81% B-
Market Capitalization 63.11B 86% B 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 120.11 30% F 7% F
Price/Book Ratio 4.00 46% F 26% F
Price / Cash Flow Ratio 41.85 21% F 9% F
EV/EBITDA 35.21 39% F 12% F
Management Effectiveness  
Return on Equity 3.69% 50% F 35% F
Return on Invested Capital 2.82% 52% F 42% F
Return on Assets 3.64% 57% F 62% D-
Debt to Equity Ratio 59.49% 33% F 57% F
Technical Ratios  
Short Ratio 4.00 41% F 27% F
Short Percent 1.68% 65% D 69% D+
Beta 0.88 70% C- 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.